InvestorsHub Logo

TOB

Followers 162
Posts 5764
Boards Moderated 1
Alias Born 09/15/2010

TOB

Re: slcimmuno post# 100304

Saturday, 05/02/2015 10:43:40 PM

Saturday, May 02, 2015 10:43:40 PM

Post# of 402834
Seems they updated the In Vitro Brilacidin antibacterial research cited in the 2006 OMIG Abstract and are reporting new In Vivo research.

As their affiliation was PolyMedix at the time of the research, it follows that would be the commercial relationship disclosed. I wonder if the (F) indicates former? It wouldn't make sense to mention Cellceutix as they weren't involved in the research being presented.

Hopefully this abstract will lead to a peer reviewed journal article on Brilacidin for ocular pathogens.

As Abstracts and articles often take months or years to get presented and published, the companies involved may be gone, but the researchers still publish, especially if in academia.

The Brilacidin journal paper was an example, published in 2014, about a year after PolyMedix was gone.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135847/






The stock market is simply the transfer of wealth from the impatient to the patient. - Warren Buffet

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News